<PAGE>   1

                                    FORM 10-Q

                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

           (x) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                  For the quarterly period ended June 30, 2000
                  --------------------------------------------
                                       or

          ( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

          For the transition period from______________ to______________


                        Commission file number 000-20805
                        --------------------------------

                          APACHE MEDICAL SYSTEMS, INC.
                          ----------------------------
             (Exact name of registrant as specified in its charter)


             Delaware                                   23-2476415
             -----------------------------------------------------
        (State or other jurisdiction of                (I.R.S. Employer
       incorporation or organization)                 Identification No.)


       1650 Tysons Boulevard, McLean, Virginia                  22102
       --------------------------------------------------------------
       (Address of principal executive offices)             (Zip Code)

                                 (703) 847-1400


              (Registrant's telephone number, including area code)
              ----------------------------------------------------
             (Former name, former address and former fiscal year, if
                           changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes X No

                                    7,452,087
                                    ---------

 (Number of shares of common stock, $.01 par value per share, outstanding as of
                                  July 1, 2000)

                                        1


<PAGE>   2




                          APACHE MEDICAL SYSTEMS, INC.

                                      INDEX

<TABLE>
<CAPTION>
                                                                                                                    PAGE NO.
                                                                                                                    --------
<S>                                                                                                                 <C>
PART I - FINANCIAL INFORMATION

Item 1.            Financial Statements

              Consolidated Statements of Operations (unaudited) for the Three
               and Six Months Ended June 30, 2000 and 1999

              Consolidated Balance Sheets for the Six Months Ended June
               30, 2000 (unaudited) and Year Ended December 31, 1999

              Consolidated Statements of Changes in Stockholders' Equity
               (Deficit) for the Six Months Ended June 30, 2000 (unaudited)
               and Year Ended December 31, 1999

              Consolidated Statements of Cash Flows (unaudited) for the Six
               Months Ended June 30, 2000 and 1999

              Notes to Consolidated Financial Statements (unaudited)

Item 2.            Management's Discussion and Analysis of Financial
              Condition and Results of Operations

Item 3.            Quantitative and Qualitative Disclosures About Market Risk

PART II - OTHER INFORMATION

Item 4.            Submission of Matters to a Vote of Security Holders

Item 6.            Exhibits and Reports on Form 8-K

Signatures

Index to Exhibits
</TABLE>

                                        2


<PAGE>   3


                          PART 1-FINANCIAL INFORMATION

Item 1. Financial Statements

                          APACHE MEDICAL SYSTEMS, INC.
                      CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (unaudited)

<TABLE>
<CAPTION>
                                                                            THREE MONTHS                       SIX MONTHS
                                                                               ENDED                              ENDED
                                                                              JUNE 30,                           JUNE 30,
                                                                     2000                   1999            2000           1999
                                                                    ------                 ------          ------         ------
                                                               (IN THOUSANDS, EXCEPT PER SHARE DATA)
<S>                                                           <C>                     <C>             <C>           <C>

Revenue                                                            $ 1,829                 $ 3,629         $ 3,412       $ 6,938

Expenses:
  Cost of goods sold                                                   778                   1,220           1,403         1,480
  Research and development                                             152                     200             299           451
  Selling, general and administrative                                1,655                   1,819           3,311         4,245
          Total expenses                                             2,585                   3,239           5,013         6,176
                                                                 -----------             -----------     -----------   -----------

Income (Loss) from operations                                         (756)                    390          (1,601)          762

Other income (expense):
  Interest income                                                       64                      83             141           175
  Interest expense                                                      (7)                     (8)            (14)          (17)
  Other, net                                                             -                       6               -             6
                                                                 -----------             -----------     -----------   -----------

Net Income (Loss)                                                  $  (699)                $   471         $(1,474)      $   926
                                                                 ===========             ===========     ===========   ===========

Basic and diluted net income (loss) per share                      $ (0.09)                $  0.06         $ (0.20)      $  0.13
                                                                 ===========             ===========     ===========   ===========

Weighted average number of shares used for calculation of net
income (loss) per share                                              7,441                   7,350           7,420         7,344
                                                                 ===========             ===========     ===========   ===========
</TABLE>

See accompanying Notes to Consolidated Financial Statements.

                                        3


<PAGE>   4


                          APACHE MEDICAL SYSTEMS, INC.
                           CONSOLIDATED BALANCE SHEETS

<TABLE>
<CAPTION>
                                                                                         JUNE 30,                DECEMBER 31,
                                                                                                  2000                    1999
                                                                                                  ----                    ----
                                                                                      (IN THOUSANDS EXCEPT SHARE DATA)
ASSETS                                                                                         (unaudited)
<S>                                                                                             <C>                      <C>
CURRENT ASSETS:
Cash and cash equivalents                                                                       $  2,348                 $  5,194
Short-term investments                                                                             1,469                    1,048
Accounts receivable, net                                                                           1,624                    3,012
Prepaid expenses and other                                                                           347                      499
                                                                                                --------                 --------
      TOTAL CURRENT ASSETS                                                                         5,788                    9,753
Other trade receivables, net of current maturities                                                    77                      104

Furniture and equipment                                                                            3,931                    3,661
Less accumulated depreciation and amortization                                                    (3,424)                  (3,222)
                                                                                                --------                 --------
                                                                                                     507                      439

Capitalized Software Costs, net                                                                    1,001                      793
Intangible assets, net                                                                               318                      377
                                                                                                --------                 --------

      TOTAL ASSETS                                                                              $  7,691                 $ 11,466
                                                                                                ========                 ========
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable                                                                                $    646                 $  1,142
Accrued expenses                                                                                     998                    1,780
Deferred revenue                                                                                   1,937                    3,220
Current maturities of long term obligations                                                          185                      163
                                                                                                --------                 --------
      TOTAL CURRENT LIABILITIES                                                                    3,766                    6,305

Deferred rent benefit                                                                                 36                        5
Obligations under capital leases, net of current maturities                                          109                        8
Notes payable - other, net of current maturities                                                       -                       35
                                                                                                --------                 --------
      TOTAL LIABILITIES                                                                            3,911                    6,353

STOCKHOLDERS' EQUITY :
Common stock, $.01 par value, authorized shares, 30,000,000 at June 30, 2000 and                      75                       74
December 31, 1999: issued and outstanding shares, 7,452,087 at June 30, 2000 and
7,381,985 at December 31, 1999

Accumulated comprehensive income-unrealized loss                                                     (13)                     (27)
Additional paid-in capital                                                                        45,944                   45,818
Accumulated deficit                                                                              (42,226)                 (40,752)
                                                                                                --------                 --------

      TOTAL STOCKHOLDERS' EQUITY                                                                   3,780                    5,113
                                                                                                --------                 --------
   TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY                                                   $  7,691                 $ 11,466
                                                                                                ========                 ========
</TABLE>


See accompanying Notes to Consolidated Financial Statements.


                                        4


<PAGE>   5


                          APACHE MEDICAL SYSTEMS, INC.
      CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)

<TABLE>
<CAPTION>
                                                                                                    ADDITIONAL      ACCUMULATED
                                                                    COMMON STOCK                      PAID-IN      COMPREHENSIVE
(in thousands, except share data)                                      SHARES         AMOUNT          CAPITAL      INCOME (LOSS)
<S>                                                                 <C>             <C>             <C>             <C>

BALANCE AT DECEMBER 31, 1997                                         7,267,756      $       73      $   45,703      $        -

Issuance of common stock under Employee Stock Purchase Plan             62,717               -              67               -

Net loss                                                                     -               -               -               -
                                                                     ---------      ----------      ----------      ----------
BALANCE AT DECEMBER 31,1998                                          7,330,473      $       73      $   45,770      $        -

Issuance of common stock under Employee Stock Purchase Plan             38,912               1              36               -

Exercise of common stock options                                        12,600               -              12               -
Unrealized gain (loss)                                                                                                     (27)
                                                                     ---------      ----------      ----------      ----------
Net income
BALANCE AT DECEMBER 31, 1999                                         7,381,985      $       74      $   45,818      $      (27)

Issuance of common stock under Employee Stock Purchase Plan             11,556               -              14               -

Exercise of common stock options                                        76,661               1             141               -
Treasury stock purchase                                                (18,115)                            (29)
Unrealized gain                                                                                                             14
                                                                     ---------      ----------      ----------      ----------
Net income
BALANCE AT JUNE 30, 2000 (unaudited)                                 7,452,087      $       75      $   45,944      $      (13)
                                                                     =========      ==========      ==========      ==========


<CAPTION>

                                                                      ACCUMULATED                     COMPREHENSIVE
(in thousands, except share data)                                       DEFICIT           TOTAL       INCOME (LOSS)
<S>                                                                   <C>             <C>             <C>

BALANCE AT DECEMBER 31, 1997                                          $  (38,910)     $    6,866         (15,918)
                                                                                                      ==========
Issuance of common stock under Employee Stock Purchase Plan                    -              67               -

Net loss                                                                  (3,193)         (3,193)         (3,193)
                                                                      ----------      ----------      ----------
BALANCE AT DECEMBER 31,1998                                           $  (42,103)     $    3,740          (3,193)
                                                                                                      ==========
Issuance of common stock under Employee Stock Purchase Plan                                   37               -

Exercise of common stock options                                                              12               -
Unrealized gain (loss)                                                                       (27)            (27)
Net income                                                                 1,351           1,351           1,351
                                                                      ----------      ----------      ----------
BALANCE AT DECEMBER 31, 1999                                          $  (40,752)     $    5,113           1,324
                                                                                                      ==========
Issuance of common stock under Employee Stock Purchase Plan                                   14               -

Exercise of common stock options                                                             142               -
Treasury stock purchase                                                                      (29)
Unrealized gain                                                                               14              14
Net income                                                                (1,474)         (1,474)         (1,474)
                                                                      ----------      ----------      ----------
BALANCE AT JUNE 30, 2000 (unaudited)                                  $  (42,226)     $    3,780      $   (1,460)
                                                                      ==========      ==========      ==========
</TABLE>


See accompanying Notes to Consolidated Financial Statements.


                                        5


<PAGE>   6




                          APACHE MEDICAL SYSTEMS, INC.
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (unaudited)


<TABLE>
<CAPTION>
                                                                                                SIX MONTHS ENDED JUNE 30,
                                                                                                 2000             1999
                                                                                               --------         --------
                                                                                              (in thousands)
<S>                                                                                             <C>              <C>
CASH FLOWS FROM OPERATING ACTIVITIES:

  Net income (loss)                                                                             $ (1,474)        $    926
  Adjustments to reconcile net income (loss) to net cash
  used in operating activities:
      Depreciation and amortization                                                                  388              418
      Provision for doubtful accounts                                                                 75              616
      Changes in operating assets and liabilities:
           Accounts receivable                                                                     1,314           (1,268)
           Other trade receivables                                                                    25               26
           Other current assets                                                                      153              117
           Accounts payable and accrued expenses                                                  (1,278)            (991)
           Deferred rent                                                                              31              (31)
           Deferred revenue                                                                       (1,283)             270
                                                                                                --------         --------
       NET CASH PROVIDED FROM (USED IN) OPERATING ACTIVITIES                                      (2,049)              83

CASH FLOWS FROM INVESTING ACTIVITIES:

  Capitalized software development costs                                                            (335)            (233)
  Purchase of furniture and equipment                                                               (270)              (8)
  Increase in short-term investments                                                                (421)             (48)
                                                                                                --------         --------
       NET CASH PROVIDED FROM (USED IN) INVESTING ACTIVITIES                                      (1,026)            (289)

CASH FLOWS FROM FINANCING ACTIVITIES:
  Principal payments on capital lease obligations                                                    159               (9)
  Principal payments on borrowings                                                                   (71)             (81)
  Proceeds from issuance of common stock under employee stock purchase plan                           14               22
  Proceeds from issuance of common stock upon exercise of options, net of treasury stock             113                -
  Unrealized gain                                                                                     14                -
                                                                                                --------         --------
       NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES                                           229              (68)

NET DECREASE IN CASH AND CASH EQUIVALENTS                                                         (2,846)            (274)

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD                                                   5,194            5,532
                                                                                                --------         --------
CASH AND CASH EQUIVALENTS AT END OF PERIOD                                                      $  2,348         $  5,258
                                                                                                ========         ========

SUPPLEMENTAL INFORMATION:
  Cash payments for interest                                                                    $     13         $     17
                                                                                                ========         ========
</TABLE>


See accompanying Notes to Consolidated Financial Statements.


                                        6



<PAGE>   7




                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                   (Unaudited)

1.    BASIS OF PRESENTATION

The accompanying consolidated financial statements have been prepared by APACHE
Medical Systems, Inc. (the "Company") pursuant to the rules and regulations of
the Securities and Exchange Commission ("SEC"). The financial information
included herein is unaudited. However, in the opinion of management, all
adjustments (which include normal recurring adjustments) considered necessary
for a fair presentation have been made. Certain information and footnote
disclosures normally included in annual financial statements prepared in
accordance with generally accepted accounting principles have been condensed or
omitted pursuant to such rules and regulations, but the Company believes that
the disclosures made are adequate to make the information presented not
misleading. For more complete financial information, these financial statements
should be read in conjunction with the audited financial statements and notes
thereto for the year ended December 31, 1999 included in the Company's Form
10-K. Results for interim periods are not necessarily indicative of the results
for any other interim period or for the full fiscal year.

Revenue for sales of systems and products are recognized at delivery. For
systems where services are critical to the functionality of the system, revenue
is recognized using contract accounting. Systems support fees are recognized
ratably over the period of performance. Professional services revenue is
recognized as these services are provided and is generally billed on a time and
material basis. Professional services do not involve significant customization,
modification or production of the licensed software. Amounts received prior to
the performance of service or completion of a milestone are deferred. Revenue
recognized for work performed for which billings have not been presented to
customers is recorded as unbilled.

2.    BASIC AND DILUTED NET INCOME (LOSS) PER SHARE

The Company has implemented Financial Accounting Standards Board ("FASB")
Statement of Financial Accounting Standards ("SFAS") Statement No. 128,
"Earnings Per Share," which requires dual presentation of basic and diluted
earnings per share. Basic loss per share includes no dilution and is computed by
dividing net loss available to common stockholders by the weighted average
number of common shares outstanding for the period. Diluted earnings per share
includes the potential dilution that could occur if securities or other
contracts were exercised or converted into common stock. Options and warrants
outstanding were not included in the computation of diluted earnings per share
as their effect would be anti-dilutive. Diluted net income (loss) per share and
basic earnings per share are identical for all periods presented.

3.    NEW ACCOUNTING PRONOUNCEMENTS

The American Institute of Certified Public Accountants ("AICPA") has issued
Statement of Position 97-2 "Software Revenue Recognition" ("SOP 97-2") that
supersedes Statement of Position 91-1. SOP 97-2 is effective for revenue
transactions entered into by the Company in fiscal years beginning after
December 31, 1997. The Company has adopted SOP 97-2 and it did not have a
material impact on the financial statements of the Company. In March 1998, AICPA
issued SOP 98-4, which defers for one year the implementation of certain
provisions of SOP 97-2. The issuance of SOP 98-4 had no effect on the Company.
In December 1998, the AICPA issued SOP 98-9, which extends the deferral date of
implementation of certain provisions of SOP 97-2 to 2000 and amends the method
of revenue recognition in some circumstances. The adoption of this SOP did not
have a significant effect on the results of operations or financial position.

4.    STOCKHOLDERS' EQUITY

Stock Options

On May 31, 2000 the Company's shareholders approved an amendment to the
Non-Employee Director Supplemental Stock Option Plan (the "Supplemental Plan"),
to increase the number of shares of the Company's Common Stock available under
the plan from 120,000 to 250,000. The amendment was effective as of January 1,
2000. On November 17, 1999, the Board of Directors granted options to acquire
8,700 shares of Common Stock to each non-employee director of the Company
subject to the approval of the amendment to the Supplemental Plan. The grant
date was effective as of January 1, 2000 and the exercise price was $1.52 per
share, which price was the fair market value of the Common Stock on that date.

                                        7


<PAGE>   8
Item 2. Management's Discussion and Analysis of Financial Condition and Results
        of Operations

RESULTS OF OPERATIONS

THREE AND SIX MONTHS ENDED JUNE 30, 2000 AND 1999

REVENUE. Revenue for the quarter ended June 30, 2000 decreased to $1.8 million
from $3.6 million in the prior year period. This decrease was related to a
significant decrease in Systems revenue. Revenue for the six months ended June
30, 2000 decreased to $3.4 million from $6.9 million in the year ago period. The
overall decrease in revenue resulted from a continuing soft market for systems
and services during the quarter. The Company believes that the current market
conditions are brought about by a combination of the Balanced Budget Amendment
of 1997, Y2K carry-over effect, and looming Health Insurance Portability and
Accountability Act of 1996 (HIPAA) concerns.

COST OF GOODS SOLD. Cost of goods sold for the quarter ended June 30, 2000
decreased to $778,000 from $1.2 million in the prior year period. This decrease
was primarily related to the decrease in revenue. Cost of goods sold for the six
months ended June 30, 2000 decreased slightly to $1.4 million from $1.5 million
in the prior year period.

SELLING, GENERAL AND ADMINISTRATIVE. Selling, general and administrative
expenses for the quarter ended June 30, 2000 decreased to $1.7 million from $1.8
million in the prior year period. This decrease was due to an overall reduction
in selling, general and administrative expenses. Selling, general and
administrative expenses for the six months ended June 30, 2000 decreased to $3.3
million from $4.2 million in the prior year period. This decrease was due
primarily to a decrease in bad debt expense as well as reductions in legal and
other selling, general and administrative expenses.

RESEARCH AND DEVELOPMENT. Research and development expenses for the quarter
ended June 30, 2000 decreased to $152,000 from $200,000 in the prior year
period. Research and development expenses for the six months ended June 30, 2000
decreased to $299,000 from $451,000 in the prior year period. The decrease was
due to an increase in capitalized software development costs and improvements in
productivity in product generation processes. This was partially offset by the
Company's repositioning program. The program is proceeding according to plan and
the rollout of the Company's Internet initiative, APACHE 2000, is on schedule.
During the six months ended June 30, 2000, capitalized software development
costs were $335,000, compared to $233,000 in the prior year period.

OTHER INCOME (EXPENSE). Other income (expense) for the quarter ended June 30,
2000 decreased to $57,000 from $81,000 in the prior year period. Other income
(expense) for the six months ended June 30, 20000 decreased to $127,000 from
$164,0000 in the prior year period. The decrease is due to a decrease in
interest income as a result of a reduction in cash.

LIQUIDITY AND CAPITAL RESOURCES

Cash and short-term investments were $3.8 million as of June 30, 2000 compared
to $6.2 million as of December 31, 1999.

The Company anticipates that funds generated from operations will be sufficient
to meet its planned ongoing operating and working capital requirements and to
finance planned product development, sales and marketing activities and capital
acquisitions through 2000. Through June 30, 2000, the Company has incurred
cumulative net operating losses of approximately $42.2 million. There can be no
assurance that the Company will be profitable in the future or that present
capital will be sufficient to fund the Company's ongoing operations. If
additional financing is required to fund operations, there can be no assurance
that such financing can be obtained or obtained on terms acceptable to the
Company.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS

Statements in this filing which are not historical facts are forward-looking
statements under provisions of the Private Securities Litigation Reform Act of
1995. All forward-looking statements involve risks and uncertainties. The
Company wishes to caution readers that the following important factors, among
others, in some cases have affected, and in the future could affect the
Company's actual results and could cause its actual results in fiscal 2000 and
beyond to differ materially from those expressed in any forward-looking
statements made by, or on behalf of, the Company.

Important factors that could cause actual results to differ materially include
but are not limited to the Company's: having sufficient sales and timely
collections to meet cash requirements and achieve profitability; ability to
attract and retain key employees; success of its strategy to concentrate its
product offerings on high-risk, high-cost patients; ability to timely develop
new products and enhance existing products; ability to compete in the
competitive and rapidly evolving healthcare information technology industry;
success of its marketing and consulting efforts and ability to effectively
utilize its direct sales force; ability to protect proprietary information and
to obtain necessary licenses on commercially reasonable terms; ability to comply
with and adopt products and services to potential regulatory changes; and
ability to adapt to economic, political and regulatory conditions affecting the
healthcare industry.

The Company's quarterly revenues and operating results have varied significantly
in the past and are likely to vary from quarter to quarter in the future.
Quarterly revenues and operating results may fluctuate as a result of a variety
of factors, including: the Company's relatively long sales cycle;

       10
<PAGE>   9



variable customer demand for its products and services; changes in the Company's
product mix and the timing and relative prices of product sales; the loss of
customers due to consolidation in the healthcare industry; changes in customer
budgets; investments by the Company in marketing or other corporate resources;
acquisitions of other companies or assets; the timing of new product
introductions and enhancements by the Company and its competitors; changes in
distribution channels; sales and marketing promotional activities and trade
shows; and general economic conditions. Further, due to the relatively fixed
nature of most of the Company's costs, which primarily include personnel costs,
as well as facilities costs, any unanticipated shortfall in revenue in any
fiscal quarter would have an adverse effect on the Company's results of
operations in that quarter. Accordingly, the Company's operating results for any
particular quarterly period may not necessarily be indicative of results for
future periods.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Information regarding the Company's investment securities as it relates to
market risk is not included as the possible effect of such risk is considered to
be immaterial.

                           PART II - OTHER INFORMATION

Item 4.  Submission of Matter to a Vote of Security Holders

(a)   The Annual Meeting of stockholders was held on May 31, 2000.


(b)   At such meeting all 7 of the nominees for election as directors were
      elected to hold office until the next Annual Meeting. The votes cast with
      respect to each nominee for election as a director were as follows:

Election of Directors: For:/Withheld: Gerald E. Bisbee, Jr., Ph.D. 5,865,638 /
72,152, Edward J. Conners 5,929,389 / 8,401, Richard Dessimoz 5,927,389 /
10,401, Peter Gladkin 5,915,837 / 21,953, Thomas W. Hodson 5,929,389 / 8,401,
William A. Knaus. M.D. 5,882,689 / 55,101, Lawrence S. Lewin 5,927,989 / 9,801.

At such meeting the shareholders approved the Amendment to the Non Employee
Director Supplemental Stock Option Plan as follows: For: 5,772,436. Against:
154,972. Abstain: 10,382.

At such meeting the stockholders ratified the appointment of Ernst & Young LLP
as the Company's independent accountants. For: 5,915,111. Against: 5,642.
Abstain: 17,037.


Item 6. Exhibits and Reports on Form 8-K

(a) Exhibits. The following Exhibits are filed herewith and made a part hereof:

<TABLE>
<CAPTION>
            Exhibit Number                          Description
            --------------                          -----------
<S>                                 <C>
            2.1                     Asset Purchase Agreement by and among the Company and Dun &
                                    Bradstreet HealthCare Information, Inc. and Cognizant
                                    Corporation dated as of December 30, 1996 (1)

            2.2                     Asset Purchase Agreement by and among the Company and Iowa
                                    Health Centers, P.C. d/b/a Iowa Heart Center, P.C., Mercy
                                    Hospital Medical Center, Mark A. Tannenbaum, M.D. and Iowa
                                    Heart Institute dated as of January 7, 1997 (1)

            2.3                     Agreement and Plan of Merger among the Company, NHA
                                    Acquisition Corporation, National Health Advisors, Ltd.,
                                    Scott A. Mason and Donald W. Seymour dated as of June 2,
                                    1997 (5)

            3.1                     Amended and Restated Certificate of Incorporation (5)

            3.2                     By-Laws (2)

            4.1                     Specimen Common Stock Certificate (2)

            4.2                     Rights Agreement between the Company and First Chicago Trust
                                    Company of New York, dated as of May 6, 1997 (3)

            10.1                    APACHE Medical Systems, Inc. Employee Stock Option Plan +(5)

            10.2                    APACHE Medical Systems, Inc. Non-Employee Director Option
                                    Plan +(5)

            10.3                    Sublease Agreement between the Company and First Union
                                    National Bank of Virginia, dated March 17, 1994 (2)

            10.4                    Registration Agreement between the Company and Certain
                                    Stockholders, dated December 28, 1995 (2)

            10.5                    Form of Warrant Agreement relating to warrants issued in 1995 (2)

            10.6                    Warrant Agreement between the Company and Venture Fund of
                                    Washington, dated May 13, 1991 (2)
</TABLE>


<PAGE>   10
<TABLE>
<S>                                 <C>
            10.7                    Licensing Agreement between the Company and Cerner
                                    Corporation, dated February 2, 1995 (2)

            10.8                    Nonqualified Stock Option Agreement between the Company and
                                    The Cleveland Clinic Foundation, dated August 19, 1994 (2)

            10.9                    Agreement between the Company and The George Washington
                                    University, dated August 19, 1994 (2)

            10.10                   Letter Agreement between the Company and the Northern New
                                    England Cardiovascular Disease Study Group, dated March 13,
                                    1995 (2)

            10.11                   Licensing Agreement between the Company and Quality
                                    Information Management Corporation, dated March 24, 1994 (2)

            10.12                   Marketing Agreement between the Company and American
                                    Healthcare Systems Purchasing Partners, L.P., dated as of
                                    June 3, 1996 (2)

            10.13                   Registration Agreement between the Company and each of Iowa
                                    Health Centers, P.C. d/b/a Iowa Heart Center, P.C., Mercy
                                    Hospital Medical Center, Mark A. Tannenbaum, M.D. and Iowa
                                    Heart Institute dated January 7, 1997 (1)

            10.14                   Nonqualified Stock Option Agreements between the Company and
                                    each of Iowa Health Centers, P.C. d/b/a Iowa Heart Center,
                                    P.C., Mercy Hospital Medical Center and Mark A. Tannenbaum,
                                    M.D., dated January 7, 1997 (4)

            10.15                   Security Agreement dated February 11, 1997 made by the
                                    Company for the use and benefit of Crestar Bank and
                                    corresponding Commercial Note (5)

            10.16                   License Agreement between the Company and Vermont Oxford
                                    Network, Inc., Related Services Agreement between the
                                    Company and Vermont Oxford Network, Inc. and Consulting
                                    Agreement between the Company and Clinimetrics, Inc. each
                                    effective as of June 24, 1997 ++(5)

            10.17                   Employment Agreement by and between the Company and Gerald
                                    E. Bisbee, Jr., Ph.D., dated May 5, 1997 +(5)

            10.18                   Employment Agreement by and between the Company and Scott A.
                                    Mason, dated June 15, 1999 +(10)

            10.19                   Nonqualified Stock Option Agreement between the Company and
                                    William A. Knaus, M.D. dated May 29, 1997 +(5)

            10.20                   APACHE Medical Systems, Inc. Employee Stock Option Plan,
                                    Amended and Restated Effective May 12, 1999 (9)

            10.21                   Form of 1998 Employment Agreement +(6)

            10.22                   Form of Nonqualified Director Stock Option Agreement +(6)

            10.23                   Employment Agreement by and between Peter Gladkin and the
                                    Company, dated May 30, 1998 +(7)

            10.24                   Employment Agreement by and between Gina Campbell and the
                                    Company, dated August 24, 1998 +(8)

            10.25                   Employment Agreement by and between Karen Miller and the
                                    the Company, dated September 30, 1998 +(8)

            10.26                   Employment Agreement by and between Violet Shaffer and
                                    the Company, dated April 28, 1998 +(9)

            10.27                   APACHE Medical Systems, Inc. Non-Employee Director
                                    Supplemental Stock Option Plan, Amended and Restated
                                    Effective May 12, 1999 +(9)

            10.28                   Employment Agreement by and between Sean Seerey and the Company,
                                    Dated May 11, 1999 (10)

            10.29                   Lease between Tysons II Development Co. Limited Partnership
                                    and the Company, dated August 16, 1999 (11)

            10.30                   Employment Agreement by and between William Knaus and
                                    the Company, dated July 28, 2000 +(12)

            10.31                   APACHE Medical Systems, Inc. Non-Employee Director Supplemental
                                    Stock Option Plan, Amended and Restated Effective January 1, 2000+ (13)

            11.1                    Computation of Earnings (Loss) Per Share (12)

            27.1                    Financial Data Schedule (12)
</TABLE>

+             Reflects management contract or other compensatory arrangement

++            Confidential treatment was requested for a portion of this Exhibit

<TABLE>
<S>                                 <C>
                    (1)             Incorporated herein by reference to the Company's Report on Form 8-K
                                    filed on January 14, 1997 (File No. 0-20805)

                    (2)             Incorporated herein by reference to the
                                    Company's Registration Statement on Form S-1
                                    (File No. 333-04106)

                    (3)             Incorporated herein by reference to the
                                    Company's Current Report on Form 8-K filed
</TABLE>
<PAGE>   11


<TABLE>
<S>                                 <C>
                                    on June 4, 1997 (File No. 0-20805)

                    (4)             Incorporated herein by reference to the
                                    Company's Report on Form 10-Q for the
                                    quarter ended March 31, 1997 (File No.
                                    0-20805)

                    (5)             Incorporated herein by reference to the
                                    Company's Report on Form 10-Q for the
                                    quarter ended June 30, 1997 (File No.
                                    0-20805)

                    (6)             Incorporated herein by reference to the
                                    Company's Report on Form 10-K for the year
                                    ended December 31, 1997 (File No. 0-20805)

                    (7)             Incorporated herein by reference to the
                                    Company's Report on Form 10-Q for the
                                    quarter ended June 30, 1998 (File No.
                                    0-20805)

                    (8)             Incorporated herein by reference to the
                                    Company's Report on Form 10-K for the year
                                    ended December 31, 1998 (File No. 0-20805)

                    (9)             Incorporated herein by reference to the
                                    Company's Report on Form 10-Q for the
                                    quarter ended March 31, 1999 (File No.
                                    0-20805)

                    (10)            Incorporated herein by reference to the
                                    Company's Report on Form 10-Q for the
                                    quarter ended September 30, 1999 (File No.
                                    0-20805)

                    (11)            Incorporated herein by reference to the
                                    Company's Report on Form 10-K for the year
                                    ended December 31, 1999 (File No. 0-20805)

                    (12)            Filed herewith

                    (13)            Incorporated herein by reference to the
                                    Company's Definitive Proxy Statement filed
                                    on April 27, 2000 (File No. 0-20805)
</TABLE>

(b)      Reports on Form 8-K

Form 8-K dated June 1, 2000 and filed June 8, 2000, for the purpose of filing
under Item 5--Other Events and Item 7--Financial Statements and Exhibits, a
press release announcing that Dr. William Knaus had been named as the
Registrant's President and Chief Executive Officer.


                                       11


<PAGE>   12




                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                        APACHE MEDICAL SYSTEMS, INC.

Date: August 11, 2000                /s/William A. Knaus
                                     -------------------

                                     William A. Knaus
                                     President and Chief Executive Officer

                                     /s/Karen C. Miller
                                     -------------------

                                     Karen C. Miller
                                     Vice President of Finance & Chief Financial
                                     Officer

                                       12


<PAGE>   13




                                INDEX TO EXHIBTS

<TABLE>
<CAPTION>
Exhibit Number               Description
                             -----------
<S>                <C>
10.30              Employment Agreement by and between William Knaus and
                       the Company, dated July 28, 2000

11.1                Computation of Earnings (Loss) Per Share

27.1                Financial Data Schedule
</TABLE>

                                       13